Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue ...

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...

More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the ...

The White House said it's moving to make the federal health insurance plans pay for anti-obesity drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound for people who are obese, even if they don ...

The Endowment made the grants through the latest round of its Religion and Cultural Institutions Initiative, a national initiative launched in 2019 that is supporting efforts to improve the public ...

The Biden administration is proposing a rule that would require the U.S. government to cover weight-loss drugs, potentially expanding access for millions of Americans with obesity and creating ...

The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over one year for patients who were obese or overweight without diabetes. In ...

The Converge platform validated as many as 83% of its treatment targets in disease models, a higher success rate than usual ...

The Biden administration is proposing a major expansion of how Medicare and Medicaid cover Wegovy and Zepbound ...

The stock decline is on track to be Amgen's (AMGN) worst one-day percentage fall since a 13.4% drop on Oct. 27, 2000, according to Dow Jones Market Data. MariTide has the advantage over rival ...

The stocks of companies that make the new class of drugs to treat obesity and manage diabetes were mostly higher early Tuesday after the Biden administration proposed a rule that would allow Medicare ...

Amgen's latest once-monthly weight loss drug data looks "OK," analysts say, as its path to approval still remains murky.